A PHASE II CLINICAL TRIAL OF ENMD-2076 IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER: TRANSLATING A P53-BASED BIOMARKER FROM BENCH TO BEDSIDE J. R. Diamond1, A.C. Tan1, T.M. Pitts1, A. van Bokhoven1, D. Aisner1, A.D. Elias1, V.F. Borges1, K.D. Miller2, S.G. Eckhardt1, J.J. Tentler1
1University of Colorado Cancer Center, Aurora, CO, USA
2Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA
Good find, TBorg. Even though it's only a poster presentation, it's good to see in a conference concentrating on Phase I studies, with only a few Phase II's there. Looks like management's getting proactive in getting some exposure.